Yang Claire Zeng

Claire Zeng is the Founder, CEO, and CTO of DoriNano, a pioneering Harvard spin-off from the Wyss Institute. Her company leverages groundbreaking DNA origami nanoparticle technology to develop precise combination immunotherapies. Claire brings nearly a decade of translational research experience from her tenure as a Senior Scientist and Instructor in Medicine at Dana-Farber Cancer Institute and Harvard Medical School. Her work is dedicated to bridging the gap between innovative nanotechnology and clinical applications in cancer treatment. Claire is a scientific entrepreneur on a mission to transform drug delivery and advance the next generation of immunotherapies.